Skip to content

Return on equity at other companies

IAR
Integra LifeSciencesIART
-38.6%
MiMedx Group logo
MiMedx GroupMDXG
13.8%-8.6pp
Orthofix Medical Inc. logo
Orthofix Medical Inc.OFIX
-13.4%-4.6pp
Bioventus logo
BioventusBVS
16.9%+10.9pp
Artivion logo
ArtivionAORT
3.1%+1.8pp
Axogen logo
AxogenAXGN
-18%-70.5pp

Other financials

Income statement

See full
Revenue$37.2M-57.1%
Gross profit$63.0M-22.5%
Operating income-$68.9M-158%
Net income-$53.2M-182%
EPS (diluted)-$0.44-159%

Balance sheet

See full
Cash & equivalents$91.4M-16.9%
Total debt$39.4M+24.8%
Total equity$244.6M+0.7%
Total assets$520.0M+11.3%

Cash flow

See full
Operating cash flow$21.1M+206%
CapEx$3.1M-13.2%
Free cash flow$18.0M+176%

Valuation

See full
Market cap$312.68M-23.7%
Enterprise value$260.72M-21.3%
P/E115×
P/S0.6×-0.3×

Profitability

See full
Gross margin75.9%+0.8pp
Operating margin0.5%
Net margin0.5%+0.3pp
FCF margin6.9%

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio3.5×-0.6×

Where this comes from

Calculated from Organogenesis Holdings Inc.’s reported figures.

Based on trailing twelve months.

The official record: Organogenesis Holdings Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organogenesis Holdings Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organogenesis Holdings Inc.'s return on equity?
Organogenesis Holdings Inc. (ORGO) reported return on equity of 1.1% in Q1 2026.
How has Organogenesis Holdings Inc.'s return on equity changed year-over-year?
Organogenesis Holdings Inc.'s return on equity increased by 118.3% year-over-year, from -6.1% to 1.1%.
What is the long-term trend for Organogenesis Holdings Inc.'s return on equity?
Over 4 years (2020 to 2025), Organogenesis Holdings Inc.'s return on equity has grown at a -7.7% compound annual growth rate (CAGR), from 18.2% to 13.2%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.